— Know what they know.
Not Investment Advice
Also trades as: 0K6R.L (LSE) · $vol 0M

NBIX NASDAQ

Neurocrine Biosciences, Inc.
1W: +2.9% 1M: +4.0% 3M: -19.2% YTD: +3.9% 1Y: +1.4% 3Y: +32.3% 5Y: +41.6%
$146.00
+0.13 (+0.09%)
 
Weekly Expected Move ±3.9%
$131 $137 $143 $148 $154
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 60 · $14.8B mcap · 100M float · 1.28% daily turnover · Short 73% of daily vol
Credit Risk of going bust: lower than 88% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.30 (down 99.8%), Neurocrine Biosciences, Inc. would be worth roughly what it owes.
Total debt $401.8M against a stock market value of $14.84B.
Distance to default 12.82 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $200.9M (short-term plus half of long-term), stock volatility 34.0%; Altman Z'' 4.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$4.6B +24.5% ▲
5Y CAGR: +21.7%
Total Liabilities
$1.4B +22.1% ▲
5Y CAGR: +17.8%
Shareholders Equity
$3.3B +25.6% ▲
5Y CAGR: +23.6%
Cash & Investments
$1.5B +37.6% ▲
5Y CAGR: +13.1%
Total Debt
$415M -8.7% ▼
5Y CAGR: +0.1%
Net Debt
-$298M -234.0% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$341M$263M$251M$233M$713M
Short-Term Investments$370M$726M$780M$843M$767M
Cash & ST Investments$711M$989M$1.0B$1.1B$1.5B
Net Receivables$186M$350M$439M$479M$687M
Inventory$30M$35M$38M$57M$69M
Other Current Assets$46M$79M$98M$112M$286M
Total Current Assets$973M$1.5B$1.6B$1.7B$2.5B
Property, Plant & Equip.$156M$146M$347M$592M$545M
Goodwill & Intangibles$0$37M$36M$42M$0
Long-Term Investments$624M$402M$849M$864M$1.2B
Other Non-Current Assets$4M$25M$50M$10M$60M
Total Non-Current Assets$1.1B$915M$1.6B$2.0B$2.1B
Total Assets$2.1B$2.4B$3.3B$3.7B$4.6B
— Liabilities —
Accounts Payable$52M$67M$133M$110M$105M
Short-Term Debt$0$169M$170M$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$133M$225M$261M$298M$424M
Total Current Liabilities$246M$538M$655M$508M$743M
Long-Term Debt$335M$0$0$0$0
Other Non-Current Liab.$12M$30M$106M$166M$220M
Total Non-Current Liabilities$453M$123M$365M$621M$635M
Total Liabilities$698M$661M$1.0B$1.1B$1.4B
— Equity —
Common Stock$100K$100K$100K$100K$100K
Retained Earnings-$636M-$407M-$157M$29M$448M
Accumulated OCI-$2M-$8M$7M$6M$13M
Total Stockholders Equity$1.4B$1.7B$2.2B$2.6B$3.3B
Total Liabilities & Equity$2.1B$2.4B$3.3B$3.7B$4.6B
— Key Metrics —
Total Debt$440M$263M$428M$455M$415M
Net Debt$100M$0$177M$222M-$298M
Total Investments$995M$1.1B$1.6B$1.7B$2.0B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms